Peer-reviewedCC BY-NC-NDJournal of gastrointestinal oncology14 Oct 2026

Tinengotinib, an arising option for FGFR inhibitor resistant cholangiocarcinoma.

Ioannis A Voutsadakis^1,2,3

¹Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
²University of Iowa Carver College of Medicine, Iowa City, IA, USA.
³Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.

Ceftazidime-avibactam as a polymyxin-sparing option for multidrug-resistant Gram-negative infections in children: a real-world comparative cohort study.
Sevgi Aslan Tuncay, Gulsen Akkoc, Ezgi Celikboya +10
BMC infectious diseases1 Jul 2026Peer-reviewedCC BY-NC-NDFull textInfectious diseaseEurope PMCDOAJ
147 JAK1- altered checkpoint inhibitor-resistant melanoma treated with intratumoral oncolytic viral therapy: a 2-patient case series
Khola Khan, Daniel H Johnson
Journal for ImmunoTherapy of Cancer8 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
Phytochemical screening as an inhibitor of β-lactamases to overcome the carbapenem-resistant of Klebsiella pneumoniae
Mahir Azmal, Jibon Kumar Paul, Md. Naimul Haque Shohan +6
Scientific Reports12 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris
Yehia Elgammal, Ehab A Salama, Nour M Alkashef +2
PLOS One26 Oct 2026Peer-reviewedCC BYFull textMicrobiology Pharmacology & toxicologyPLOSEurope PMC
In Vitro and In Vivo Efficacy of the Broad-Spectrum β-Lactamase Inhibitor APC24-7 in Combination with Meropenem Against Carbapenem-Resistant Enterobacterales.
Carina Sofia Silva Matias, Klaus Skovbo Jensen, Henrik Hasman +6
Antibiotics (Basel, Switzerland)12 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeX

@article{voutsadakis2026tinengotinib,
  title = {{Tinengotinib, an arising option for FGFR inhibitor resistant cholangiocarcinoma.}},
  author = {Ioannis A Voutsadakis},
  journal = {Journal of gastrointestinal oncology},
  year = {2026},
  month = oct,
  doi = {10.21037/jgo-2026-0776},
  url = {https://europepmc.org/article/MED/42996557},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - Tinengotinib, an arising option for FGFR inhibitor resistant cholangiocarcinoma.
AU  - Ioannis A Voutsadakis
PY  - 2026
DA  - 2026/10/14
JO  - Journal of gastrointestinal oncology
DO  - 10.21037/jgo-2026-0776
UR  - https://europepmc.org/article/MED/42996557
SN  - 2078-6891
SN  - 2219-679X
ER  -

Related

Cite